What are the instructions for use of ritexitinib?

Ritlecitinib is an oral JAK inhibitor, mainly used to treat immune diseases caused by abnormalities in the JAK-STAT signaling pathway, especially for the treatment of immune-related diseases such as moderate to severe atopic dermatitis (AD) in adults and adolescents. It suppresses inflammatory responses and reduces symptoms of diseases such as atopic dermatitis by selectively inhibiting Janus kinases (JAK) 1 and JAK3. The following is the main content of the instructions for use of ritexitinib, covering indications, usage and dosage, adverse reactions, precautions, etc.

1. Indications

Ritexitinib is approved for the treatment of adults and adolescents 12 years of age and older with moderate to severe atopic dermatitis (AD ), particularly those who are refractory to or intolerant to topical treatments. Atopic dermatitis is a chronic, recurring skin inflammation in which patients often present with severe itching, skin damage, and inflammation. Ritexitinib regulates the function of the immune system and inhibits excessive immune responses caused by the JAK-STAT pathway, thereby alleviating skin symptoms and improving quality of life.

2. Usage and dosage

The recommended starting dose of ritixitinib is 50 mg once daily in adults and adolescents (12 years and older). Your physician may adjust dosage based on clinical response and tolerability. Dosage adjustments may be necessary in patients with insignificant clinical effects or adverse reactions. During treatment, patients should be followed up regularly to evaluate the efficacy and tolerability of the drug.

This medication is taken by mouth and can be taken with or on an empty stomach. Ritexitinib tablets should be swallowed whole and not crushed, chewed or crushed. During medication, if you miss a dose, you should take it as soon as possible on the day you remember, but if it is close to the time of your next dose, you should skip the missed dose and take the next dose at your regular time. Do not take a double dose at one time.

3. Adverse reactions

Like otherJAK inhibitors, ritexitinib may cause some side effects, although most side effects are mild or moderate and resolve when the drug is discontinued or the dose is adjusted. Common adverse reactions include:

Infection: dueJAKInhibitors affect the immune system, so patients may be at increased risk of infection while taking them. Common types of infections include upper respiratory tract infections, urinary tract infections, etc. Patients should pay attention to symptoms such as elevated body temperature, cough, and frequent urination during use, and report to the doctor in time.

Gastrointestinal reactions: such as nausea, vomiting, diarrhea, etc., are usually mild and can be alleviated by adjusting diet or symptomatic treatment.

Abnormal liver function: A small number of patients will experience elevated transaminases during medication, usually manifesting as mild or moderate liver function abnormalities. Therefore, it is recommended to check liver function regularly during treatment.

Blood system reactions: such as anemia, leukopenia or thrombocytopenia, etc. Regular blood routine examination is required to detect abnormalities as early as possible.

For the above adverse reactions, patients should follow the doctor's advice. If the symptoms are severe, the doctor may adjust the dose or suspend treatment.

4. Precautions

Risk of infection: Ritexitinib may increase the risk of infection by suppressing parts of the immune system. Patients should pay special attention to avoid contact with known sources of infection during medication, and seek medical attention immediately if symptoms of infection occur. For patients with active infection, medication should be started after the infection is completely controlled.

Liver function monitoring: Because ritexitinib may cause abnormal liver function, patients need to have their liver function checked regularly during treatment, especially in the early stages of use. If symptoms of abnormal liver function occur (such as jaundice, right upper quadrant pain, etc.), the drug should be stopped in time and seek medical treatment.

Hematology monitoring: Ritexitinib may affect the number of blood cells, leading to a decrease in white blood cells, platelets, or red blood cells. Therefore, patients need to undergo regular blood routine examinations during treatment to ensure the health of the blood system.

Use During Pregnancy and Breastfeeding: The potential harm to the fetus from ritexitinib has not been established, so use of ritexitinib should be avoided in pregnant women or women planning to become pregnant. If you are breastfeeding, you should consult your doctor to evaluate whether to continue using the medication, or to consider discontinuing the medication or changing your treatment regimen.

Renal Impairment: The safety and efficacy of ritexitinib have not been fully established in patients with severe renal impairment. Therefore, it should be used with caution in such patients and the dose should be adjusted if necessary.

Drug Interactions: Ritexitinib may interact with certain drugs, especially those related to theCYP450 enzyme system. Therefore, patients should inform their physician of all medications they are taking while taking rituxitinib so that potential drug interactions can be evaluated.

5. Storage and packaging

Ritexitinib should be stored at room temperature, away from moisture and heat. Packaging containers should be sealed and stored out of reach of children. The common specifications are 20mg tablets, which are distributed according to the dosage prescribed by the doctor.

In summary, ritixitinib is a new type of JAKInhibitors provide an effective drug option for the treatment of atopic dermatitis and other immune diseases. During use, patients should use the drug strictly in accordance with the dosage and medication time requirements under the guidance of a doctor, and conduct necessary examinations regularly to ensure the therapeutic effect and minimize the occurrence of adverse reactions. At the same time, patients should maintain communication with their doctors during treatment and report any discomfort symptoms in a timely manner.

Reference materials:https://www.litfulo.com/